Navigation Links
Regional Biotech Association Urges Support for Biosimilars Bill in Congress
Date:9/22/2009

BOSTON, Sept. 22 /PRNewswire/ -- A vast coalition of New England business leaders today joined the New England Biotech Association (NEBA) to push for Congress to approve a legislative pathway for biosimilars that protect patient safety but also provide sufficient incentives for new innovative products to be developed.

NEBA and 27 other organizations and biotechnology leaders across New England said in a letter to all members of the New England congressional delegation that the biosimilars legislation is the single biggest issue in protecting the future viability and growth of New England's biotechnology industry: "New biologic medicines represent the greatest hope for treating diseases such as cancer, asthma, Parkinson's, and Alzheimers. It is crucial that biosimilars legislation preserve the incentives necessary for biotech researchers to develop the next breakthrough medical treatments. These incentives should include an appropriate period of 12-years of data exclusivity to allow New England's biotech companies to attract and protect the massive investment necessary to develop a biologic."

During its recent consideration of health care reform legislation, both the Senate Health, Education, Labor and Pensions (HELP) Committee and the House Energy and Commerce Committee adopted bipartisan amendments that provide a safe, effective and reasonable pathway for the approval of biosimilars. These amendments, approved by overwhelmingly bipartisan votes, strike the right balance between expanding competition to lower costs for consumers and preserving incentives for continued biomedical innovation by providing a 12-year period of data exclusivity.

If the final legislation approved by Congress does not protect patient safety and provide sufficient incentives for investment in innovative new biologic medicines, it would deliver a devastating blow to the hope held by millions of patients and seriously undermine the region's biotech sector."

As the regional policy and public affairs voice for the biotechnology and biopharmaceutical community, NEBA represents state biotech associations, companies, academic institutions, and other organizations from all six New England states.

To find out more about NEBA, visit www.newenglandbiotech.org


'/>"/>
SOURCE New England Biotech Association
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
2. A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens
3. onTargetjobs Announces Acquisition of RegionalHelpWanted.com
4. JobLoft.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
5. BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
6. Hcareers.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
7. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
8. New Regional Biotech Association Formed
9. Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission
10. Regional Biotech Association Warns Vermont Legislation Could Have Profound Negative Impact
11. Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Nova Oculus Partners has ... pioneering medical device for the treatment of Age-Related Macular Degeneration. , The company’s ... global regulatory consultancy that helps companies like ours secure government approvals for their ...
(Date:1/21/2017)... 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... the licensing, development and commercialization of innovative biopharmaceutical products ... Company in North America 2016. ... based on the FDA approval of three innovative ... ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... how current market conditions have influenced the most recent ... Regulus Therapeutics Inc. (NASDAQ: RGLS ), Abeona ... Inc. (NASDAQ: TBPH ), and Sage Therapeutics ... new research report by Grand View Research, global Biotech market size ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... Technologies, announced today the next evolution in spinal fusion, the MISquito Percutaneous ... contrast to the competition, SpineFrontier is focused on technique driven product solutions ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
(Date:12/16/2016)... NEW YORK , Dec. 16, 2016 The global ... reach USD 12.14 billion by 2021 from USD 5.31 billion in ... ... market is mainly driven by technological advancements in medical devices, launch ... devices, rising preference for wireless connectivity among healthcare providers, and increasing ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):